Phase II Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal Cell Carcinoma

BACKGROUND: Patients with sarcomatoid renal cell carcinomas (sRCC) have poor outcomes and limited treatment options. Pre-clinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase II trial to evaluate the effic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Genitourin Cancer
Autors principals: Maiti, Abhishek, Nemati-Shafaee, Maryam, Msaouel, Pavlos, Pagliaro, Lance C., Jonasch, Eric, Tannir, Nizar M., Shah, Amishi Y.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5809227/
https://ncbi.nlm.nih.gov/pubmed/28870517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.07.028
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars